Panel Discussion - November 30, 2016


Drug Pricing in 2016: Implications for Biotech, Pharma, and the Future of Healthcare

Drug pricing is arguably THE industry topic of 2016.  Pharma continues to receive pushback from patient advocacy groups and governments on pricing, in some cases leading to suggestions of eliminating high priced drugs entirely from federal healthcare reimbursement programs.  Do new drugs really cost too much?  Some pharmaceutical manufacturers seem to raise prices arbitrarily and absurdly. Why?

This panel will discuss what really goes into setting a price for a new drug or biologic.   How do we reward and foster innovation in drug pricing, while maintaining affordability for patients? How do drug manufacturers provide value to the healthcare system while rewarding shareholders? How does the negative press impact investor sentiment and valuation?  What role will the growing generics and biosimilars industry hold in creating downstream solutions for affordability? When and how may the industry expect to see government regulation in pricing, not just FDA regulation in drug development?

In this panel discussion we take a closer look at drug pricing and value determination from the perspective of a diverse set of stakeholders in the healthcare ecosystem.
Discussion Outline:

  • Why does pharma/biotech pricing appear to be erratic?  How are pricing dynamics different across regions (e.g., US vs other countries)?
  • Why is pharma/biotech pricing viewed as a complex and dysfunctional web of winners versus losers (investors, drug manufacturers, payers, providers, patients/society)? What would a “healthy ecosystem” look like in the drug pricing arena?
  • What are macro level trends and potential changes (e.g., patient cost sharing, biosimilars, regulation), and what are the potential effects on pharma/biotech pricing?
  • From the perspective of payers, what conditions influence price, payment (reimbursement), value, affordability?
  • From the perspective of providers and patients, why is affordability crucial and what are some essential considerations and factors in the doctor-patient relationship when choosing to (or not to) prescribe a new medicine?
  • From the perspective of early stage entrepreneurs and investors, which factors drive product pricing and valuation over time?
  • From the perspective of pre-market to post-market biopharmaceutical companies, what are the key considerations to support product pricing and value?

DATE: November 30, 2016
LOCATION: DLA Piper | 2000 University Ave, Palo Alto, CA 94303
4:00pm | Registration & Networking  
5:00pm | Panel event – Q&A
6:15pm | Networking
7 pm    | Close

$25 for early registration thru Fri Nov 14
$30 for pre-registration thru Mon Nov 28
$40 for walk-ins


BIOGRAPHIES (alphabetic order)
Jonathan Freudman, MD, (Panelist) has over thirty years of experience in healthcare encompassing a wide range of clinical, administrative and business challenges. He established Freudman Healthcare Consulting LLC in 2002. His clients include venture capital, medical device and other biotechnology companies. Core competencies include planning and implementation of effective
reimbursement strategies.

Previously, Dr. Freudman managed Blue Shield of California’s Medical Policy Department. His responsibilities included new technology assessment, medical policy, disease management programs and clinical guideline development. He chaired the health plan’s Pharmacy and Therapeutics committee and served on the national Blue Cross Blue Shield Association (BCBSA) Medical Policy Committee.

His career includes 16 years of the practice of general internal medicine at Kaiser Permanente Medical Center in San Rafael, California. Administrative duties at this facility included Department Chief of Internal Medicine as well as the Medical Center’s Chief of Quality. He served on the Board of Directors of the Marin County Medical Society.

Dr. Freudman is Board Certified in Internal Medicine with added qualification in Geriatrics. He is a Fellow in the American College of Physicians and is a graduate of the George Washington University School of Medicine. He is a faculty member of University of California at San Francisco (UCSF) School of Medicine. Dr. Freudman is volunteer at the San Rafael RotoCare free clinic for the indigent and serves on the clinic’s Advisory Board.

Lisa Hagerty-McMahon (Moderator) is President of Hagerty McMahon Biotech Consulting LLC, President and Chairman of the BioPharma Consortium and Business Advisor for Maverick’s Capital LLC.

She brings deep expertise in value-driven alliance & program leadership in the life sciences and biopharmaceutical industries. Her track record in alliances spans the gamut of the small biotech / large pharmaceutical relationship model as well as the complex public-private partnership arena involving multiple pharmaceutical, government and academic partners.

Successful therapeutics in her repertoire include Naglazyme (2004-5), Orencia (2005), Vibativ (2007-9), Xtandi (2012) and Avycaz (2014-15). She is currently working on a 6th late-stage product expected to launch in 2017. Lisa is also a business advisor for Maverick’s Capital and works with small biotech companies in deal sourcing and evaluation. Additionally, Lisa brings recent large pharmaceutical M&A experience, leading development teams through asset evaluation and diligence. 

She brings over a decade of consulting experience and founded Hagerty McMahon Biotech Consulting in 2009.  She spent her early career in clinical trials at the Stanford University School of Medicine, upon completion of her thesis investigating homocysteine and other risk factors for heart disease at Stanford and BS from the University of New Hampshire. Lisa is founder of the BioPharma Consortium (BPC), a life science network organization dedicated to bringing together leading-edge science, medicine and business through high-quality, extensive and collaborative networks of life sciences professionals in San Francisco and Boston.

Nina Hill, PhD, (Panelist) is currently an Executive Director of Epidemiology, HEOR and Observational Research at Relypsa, a mid-size biotech that is part of the Galenica Group. She received her PhD from the University of Washington in Health Economics and Outcomes Research (HEOR) and an MS in epidemiology.  Her career path has taken her from the Kaiser Permanente Division of Research to Genentech, where she had responsibilities for HEOR in several different therapeutic areas.  Prior to joining Relypsa she built the HEOR functions at Affymax and Medivation where she was Senior Director, HEOR and Epidemiology.

Dr. Hill is a Health Economics expert in oncology claims analyses and economic modeling and has also served as a Member of the Blue Cross Technology Evaluation Committee for Oncology Pharmacogenomics.

Kuo Tong (Panelist) is President and Founder of Quorum Consulting.
Mr. Tong is an expert in understanding and managing economic, financial, and reimbursement forces in order to influence product acceptance and utilization. His consulting engagements focus on strategic planning and implementation in early phases of product development, during clinical evaluation, and following regulatory approval. Mr. Tong has worked across a number of different clinical specialties and therapeutic categories including: hematology and oncology; solid organ and bone marrow transplantation; infectious diseases like HIV/AIDS and hepatitis; cardiovascular diagnostics and therapeutics; dermatology; orthopedic surgery; and anesthesiology/pain medicine.

Mr. Tong is an active member of numerous professional organizations and societies including: the Academy of Managed Care Pharmacy; American Public Health Association; American Society for Blood and Marrow Transplantation; American Society of Clinical Oncology; Infectious Disease Society of America; International Society for Heart and Lung Transplantation; International Society for Pharmacoeconomics and Outcomes Research; and Society for Investigative Dermatology.

Prior to founding Quorum Consulting, Mr. Tong was a senior associate with Corning HTA (now known as Covance), a Washington, DC health care consulting firm. Prior to entering the consulting field, Mr. Tong was active in clinical and health services research at the University of California at Los Angeles Neuropsychiatric Institute and the University of Pennsylvania Department of Medicine. Mr. Tong holds degrees from the University of Pennsylvania (Philadelphia, PA) and Johns Hopkins University (Baltimore, MD).